ACC.24: Late-Breaking Science Video Collection

Published: 06 April 2024

  • Views:

    Views Icon 4960
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.

 

To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.

 

For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.

 

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

More from this programme

Part 1

View from the Thoraxcenter

In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24. 

Part 2

Late-Breaker Discussion Series

Part 5

Behind the Heart

Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.

About the episode

ACC.24 — Dr Brian Bergmark (Brigham and Women's Hospital, Harvard Medical School, US) joins us in this interview to discuss the findings of a study into olezarsen, previously known as AKCEA-APOCIII-LRx, in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease (ASCVD), with or without severe hypertriglyceridemia (NCT05355402).

This multicenter, randomized, double-blind study included 152 participant with hypertriglyceridemia (triglycerides > 150mg/dL) and established or increased risk of ASCVD. The study involved an 8-week screening period, a 23-week treatment period and a 13-week follow-up period. Patients were randomized 1:1 to recieve either olezarsen adminstered by injection once every 4 weeks, or placebo.

Findings suggest that in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, 50mg or 80mg olezarsen monthly significantly reduced triglyceride levels, as well as meaningful reductions in apolipoprotein B and non-high-density lipoprotein cholesterol, both of which are markers of atherogenic risk.

Interview Questions: 

  1. What is the reasoning behind this study?
  2. Could you tell us the mechanism of action of olezarsen
  3. What was the patient population and study design?
  4. What are the key findings?
  5. What are the implications of these findings on clinical practice?
  6. Where are the knowledge gaps?
  7. What are the next steps?

Recorded onsite at the ACC Conference in Atlanta, 2024.

Faculty Biographies

Brian Bergmark

Associate Physician in Interventional Cardiology

View full profile

Comments

You must be to comment. If you are not registered, you can register here.